ABSTRACT:
Respiratory infections pose a significant global threat to public health, contributing substantially to morbidity and mortality. This review explores the evolution of inhalation therapy, focusing on the transition from traditional Metered Dose Inhalers (MDIs) to contemporary Dry Powder Inhalers (DPIs), which have become pivotal in drug delivery to the lungs. The narrative begins with early nebulizers and atomizers, progressing through the challenges and developments of MDIs, ultimately leading to the emergence of DPIs. The review meticulously examines the advantages of DPIs over MDIs, encompassing technological innovations, enhanced patient experiences, and clinical efficiency across various respiratory conditions. Regulatory milestones and market dynamics are scrutinized, highlighting shifts in preferences among healthcare professionals and patients. Challenges encountered in DPI development are discussed, offering insights into obstacles and potential solutions. The article addresses the future prospects of inhalation therapy, exploring emerging technologies and ongoing research. In summary, this comprehensive evaluation underscores the profound impact of transitioning to DPIs in respiratory drug delivery, aiming to be a valuable resource for research, clinical, and industry professionals navigating the dynamic landscape of inhalation therapy.